Journal
MOLECULES
Volume 27, Issue 3, Pages -Publisher
MDPI
DOI: 10.3390/molecules27030797
Keywords
Huperzine A; molecular dynamics simulation; fluorescence spectroscopy; human serum albumin; neurodegenerative disorders; drug-protein interactions
Funding
- Research Supporting Project, King Saud University, Riyadh, Saudi Arabia [RSP-2021/352]
Ask authors/readers for more resources
This study investigated the binding of Huperzine A with human serum albumin (HSA) using computational methods. The results of molecular docking and molecular dynamic simulation showed interactions between Huperzine A and HSA, which were further validated by experimental assays. These findings suggest that Huperzine A may be a potential drug for Alzheimer's disease treatment.
Human serum albumin (HSA) is the most abundant protein in plasma synthesized by the liver and the main modulator of fluid distribution between body compartments. It has an amazing capacity to bind with multiple ligands, offering a store and transporter for various endogenous and exogenous compounds. Huperzine A (HpzA) is a natural sesquiterpene alkaloid found in Huperzia serrata and used in various neurological conditions, including Alzheimer's disease (AD). This study elucidated the binding of HpzA with HSA using advanced computational approaches such as molecular docking and molecular dynamic (MD) simulation followed by fluorescence-based binding assays. The molecular docking result showed plausible interaction between HpzA and HSA. The MD simulation and principal component analysis (PCA) results supported the stable interactions of the protein-ligand complex. The fluorescence assay further validated the in silico study, revealing significant binding affinity between HpzA and HSA. This study advocated that HpzA acts as a latent HSA binding partner, which may be investigated further in AD therapy in experimental settings.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available